Practitioner's Docket No.: 49032-FWC



PATENT POP JUN -8 AM 10:
GROUP 1800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:

08/901,612

Filed:

July 28, 1997

Inventor:

Bruce L. Frank, et al.

Title:

OLIGONUCLEOTIDES SPECIFIC FOR HEPATITIS B VIRUS

Assistant Commissioner for Patents Washington, D.C. 20231

POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST (REVOCATION OF PRIOR POWERS)

As assignee of record of the entire interest of the above identified patent,

REVOCATION OF PRIOR POWERS OF ATTORNEY

all powers of attorney previously given are hereby revoked and

NEW POWER OF ATTORNEY

the following practitioners are hereby appointed to prosecute and transact all business in the Patent and Trademark Office connected therewith.

(list name and registration number)

Peter F. Corless, Registration No. 33,860
David G. Conlin, Registration No. 27,026
George W. Neuner, Registration No. 26,964—
Linda M. Buckley, Registration No. 31,003—
Peter J. Manus, Registration No. 26,766—
Cara Z. Lowen, Registration No. 38,227—
William J. Daley, Jr., Registration No. 35,487—
Robert L. Buchanan, Registration No. 40,927—
Christine C. O'Day, Registration No. 38,256—
Richard E. Gamache, Registration No. 39,196—
Lisa Swiszcz, Registration No. 44,368—

SEND CORRESPONDENCE TO:

(Title)

DIRECT TELEPHONE CALLS TO:

Peter F. Corless Dike, Bronstein, Roberts & Cushman, LLP 130 Water Street Boston, MA 02109 Peter F. Corless (617) 523-3400

Customer No.: 21874						
IDENTIFICATION OF ASSIGNEE:						
Hybridon, Inc. (type or print identity of assignee of entire interest) 620 Memorial Drive 155 Footune Blvd. Cambridge, MA-02139 Mulford, MA 01757 Address						
Ownership by the Assignee is established in Assignment: Recorded at the USPTO on: June 2, 1997 Reel: 8543 Frame: 0870						
ASSIGNEE STATEMENT						
Attached to this power is a "STATEMENT UNDER 37 C.F.R. 3.73(b)." Liery The Lording Date: May 6/99 Signature						
Cheryl M. Northrup (type or print name of person authorized to sign on behalf of assignee) Vice President and General Counsel						

49032-FWC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

In re application of: Bruce L. Frank, et al. Application No.: 08 / 901,612 Group No.: 1635 Filed: July 28, 1997 For: "Oligonucleotides Examiner: Thomas G. Larson, Ph.D. Specific For Hepatitis B Virus" Issue Date: _ Patent*: Issue Date: _ Reexamination No.: Issue Date: _ Reissue: *NOTE: Insert name(s) of inventor(s) and title for patent.

Assistant Commissioner for Patents Washington, D.C. 20231

ner's Docket No.

STATEMENT UNDER 37 C.F.R. § 3.73(b)— ESTABLISHING RIGHT OF ASSIGNEE TO TAKE ACTION

CERTIFICATION UNDER 37 C.F.R. \$\$ 1.8(a) and 1.10* (When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

Ø	deposited with the United States Postal Service For Patents, Washington, D.C. 20231	rice in an envelope addressed:to:ttie:Assistant Commissioner
	37 C.F.R. § 1.8(a)	37 C.F.R: § 1.10
X	with sufficient postage as first class mail.	as "Express Mail Rost Office to Addressee" Mailing Label No(mandatory)
	TF	RANSMISSION
	transmitted by facsimile to the Patent and Tr	Latricia a. Barnes
		Signature
Da	te: <u>05/27/99</u>	Patricia A. Barnes
		(han an arist annual of annual aristical)

(type or print name of person certifying)

*WARNING: Each paper or fee filed by Express Mail must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. § 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

NOTE: 37 CFR 3.73(b) states: "When an assignee seeks to take action in a matter before the Office with respect to a patent application, . . ., patent, registration, or reexamination proceeding, the assignee must establish its ownership of the property to the satisfaction of the Commissioner. Ownership is established by submitting to the Office, in the Office file related to the matter in which action is sought to be taken, documentary evidence of a chain of title from the original owner to the assignee (e.g., copy of an executed assignment submitted for recording) or by specifying (e.g., reel and frame number) where such evidence is recorded in the Office. The submission establishing ownership must be signed by a party authorized to act on behalf of the assignee. Documents submitted to establish ownership may be required to be recorded as a condition to permitting the assignee to take action in a matter pending before the Office."

NOTE: "Section 3.73(b) is amended to remove the sentence requiring an assignee to specifically state that the evidentiary documents have been reviewed and to certify that title is in the assignee seeking to take action. The sentence is deemed to be unnecessary in view of the amendment to §§ 1.4(d) and 10.18." Notice of Oct. 10, 1997, 62 Fed. Reg. 53,131, at 53,174.

1. The assignee(s) of the entire right, title and interest hereby seek(s) to take action in the PTO in this matter.

IDENTIFICATION OF ASSIGNEE

Hybridon, Inc.

Name of assignee

Corporation

Type of assignee, e.g., corporation, partnership, university, government agency, etc.

PERSON AUTHORIZED TO SIGN

Cheryl M. Northrup

(type name of person authorized to sign on behalf of assignee)

Vice President and General Counsel

Title of person authorized to sign

NOTE: The Notice of April 30, 1993 (1150 O.G. 62-64) points out:

"The statement under 37 CFR 3.73(b) may be signed on behalf of the assignee in the following two manners if the assignee is an organization (e.g., corporation, partnership, university, government agency, etc.).

"(1) The statement may be signed by a person in the organization having apparent authority to sign on behalf of the organization. An officer (president, vice-president, secretary, or treasurer) is presumed to have authority to sign on behalf of the organization. The signature of the chairman of the board of directors is acceptable, but not the signature of an individual director. A person having a title (manager, director, administrator, general counsel) that does not clearly set forth that person as an officer of the assignee is not presumed to be an officer of the assignee or to have authority to sign the statement on behalf of the assignee. A power of attorney from the inventors in an organization to a practitioner to prosecute a patent application does not make the practitioner an official of an assignee or empower the practitioner to sign the statement on behalf of the assignee.

"(2) The statement may be signed by any person, if the statement includes an averment that the person is empowered to sign the statement on behalf of the assignee and, if not signed by a registered practitioner, the statement must be in oath or declaration form. Where a statement does not include such an averment, and the person signing does not hold a position in the organization that would give rise to a presumption that the person is empowered to sign the statement on behalf of the assignee, evidence of the person's authority to sign will be required."

[Author's Note: The requirement for an oath or declaration for this statement by a person not a registered practitioner was rescinded by the rules effective December 1, 1997.]

(complete the following, if applicable)

I, the person signing below, state that I am empowered to sign this statement on behalf of the assignee.

(Statement under 37 C.F.R. § 3.73(b) — Establishing Right of Assignee to Take Action [16-16]—page 2 of 4)

BASIS OF ASSIGNEE'S INTEREST

Ownership by the assignee is established as follows:

A.			*			
1. [2	An assigned recorder	d in the PT	O at			tified above, which was
		Ree	8543	$_{-}$, Frame $_{-}^{08}$	870	
2.] An assig	gnment (do	cument) sep	arately being	submitted	i for recordal herewith.
		<u>-</u>	A	ND/OR		
B. 🗆	A chain of	title from th	ne inventor(s) to the curre	ent assigne	e as shown below:
						_
	1. Fron	n:				_
			Name of	inventor(s)		
	To: .			 		<u>.</u>
						Recorded in PTO: Reel Frame
	2. Fron	n:				
-				or(s) or assign		-
	To:					_
						Recorded in PTO: Reel
						Frame
	3. Fron	n:				
		Na	ame of invent	or(s) or assign	ee	-
	To:				<u>. </u>	-
						Recorded in PTO: Reel
		(check ite	m below, ar	nd add details	s. if applica	able)
ſ	Addition					e attached Supplemental
	Sheet.					o diadilod odppoliidilai
	C	OPIES O	F DOCUMI	ents in Ch	IAIN OF	TITLE
		(comple	ete this item	if copies are	e being se	nt)
(Copies as follo	of the assig ws:	nment(s) or o	other docume	nt(s) in the	chain of title are attached
		A	1	□ 2		
		В	□ 1	□ 2	□ 3	
(Churtour	 ont under 27					. A.M. 240 400

(Statement under 37 C.F.R. § 3.73(b) — Establishing Right of Assignee to Take Action [16-16]—page 3 of 4)

(Signature of authorized person)

Cheryl M. Northrup

(type or print name of authorized person)

Vice President and General Counsel

Chusti C. OVa

Title of authorized person

Reg. No.: 38,256

Tel. No.: (617) 523-3400

Customer No.: 21874

SIGNATURE OF PRACTITIONER

Christine C. O'Day

(type or print name of practitioner)

Dike, Bronstein, Roberts & Cushman, LLP

P.O. Address

130 Water St., Boston, MA 02109-4280

VERIFIED STATEM STATUS (37 CFR	Docket No. 49032-FWC (1956)						
Serial No.	Filing Date	Patent No.		Issue Date			
08/901,612	July 28 1997 E						
Applicant/ Bruce L. Frank, Patentee:	JUN U 1 1553						
Invention: OLIGONUCLI	EOTIDES SPECTEL FORTEP	ATITIS B VIRUS					
I hereby declare that I am:							
☐ the owner of the	small business concern identifie	d below:					
an official of the s	mall business concern empowe	red to act on behalf of the conc	ern ider	ntified below:			
NAME OF CONCERN:	Hybridon, Inc.	,					
ADDRESS OF CONCERN	620 Memorial Drive, Cambrid	ge , MA 02139 155 F	DRIU	NE BLVD. 01757			
I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control both.							
-	under contract or law have bee to the above identified inventio	· · · · · · · · · · · · · · · · · · ·	the sm	all business concern			
☐ the specification	on filed herewith with title as liste	ed above.					
the application	identified above.						
☐ the patent ide	ntified above.						
organization having rights person, other than the inv	above-identified small business to the invention is listed on the entor, who could not qualify as ualify as a small business cond	next page and no rights to the an independent inventor under	e inven er 37 C	tion are held by any FR 1.9(c) or by any			

obligation und	der contract	or law to ass	sign, grant, con	nave assigned, granted, cover, or license any rights in			
	•	-	organization ex				
⊠ eac	n such pers	on, concern	or organization	is listed below.			
FULL NAME		chnologies, l		Ouch as H3V 440			
ADDRESS	230 Bernard	Individual	iite 212, Lavai, (Quebec H7V 4A9 Small Business Concern		Nonprofit Organization	
FULL NAME		maividaai	.	Ontain business concern	.	Tromprom Organization	
ADDRESS							
		Individual		Small Business Concern		Nonprofit Organization	
FULL NAME							
ADDRESS							
-		Individual		Small Business Concern		Nonprofit Organization	
FULL NAME ADDRESS							
ADDICESS		Individual		Small Business Concern		Nonprofit Organization	
•			•	ach named person, concer	rn or organiza	ation having rights to the	
invention ave	erring to their	r status as s	mall entities. (3	37 CFR 1.27)			
entitlement t	to small ent	ity status p	rior to paying,	or patent, notification of an or at the time of paying as a small entity is no longe	, the earliest	of the issue fee or any	
information a willful false s Title 18 of th	and belief ar statements a e United Sta	e believed to and the like s ates Code, a	o be true; and so made are po nd that such wi	of my own knowledge are further that these statemer unishable by fine or imprisoulful false statements may just verified statement is dire	nts were made onment, or bot eopardize the	e with the knowledge that the children with the winder Section 1001 of	
NAME OF PE	RSON SIGN	IING:	Cheryl M. No	rthrup			
TITLE OF PE	RSON SIGN	ING					
OTHER THAN	OWNER:		Vice Presiden	t and General Counsel			
ADDRESS OF	PERSON S	SIGNING:	Hybridon, Inc.				
			620 Memorial Drive 155 FORTUNE BLUD				
	-		Cambridge, MA 02139 MILFORD, MA 01757				
SIGNATURE:	Guer	etn.	horthru	O DATI	E: <u>/lay 6</u>	,1999	

VERIFIED STATEME STATUS (37 CFR 1	Docket No. 49032-FWC (1956)						
Serial No. 08/901,612	Filing Date	Patent No.		Issue Date			
Applicant/ Bruce L. Frank, Patentee:	et al. JUN 0 1 1999 6						
Invention: OLIGONUCLE	OTIDES SPACED FOR HEPA	ATITIS B VIRUS					
I hereby declare that I am:							
	mall business concern identified mall business concern empowe		ern ider	ntified below:			
NAME OF CONCERN:	OriGenix Technologies, Inc.	·					
ADDRESS OF CONCERN:	230 Bernard-Belleau, Suite 212	, Laval, Quebec H7V 4A9					
I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control both.							
	under contract or law have bee to the above identified invention	•	the sma	all business concern			
☐ the specification	n filed herewith with title as liste	ed above.					
the application	identified above.						
☐ the patent iden	tified above.						
organization having rights t person, other than the inve	bove-identified small business o the invention is listed on the entor, who could not qualify as ualify as a small business conc	next page and no rights to the an independent inventor under	e invent er 37 Cl	tion are held by any FR 1.9(c) or by any			
•							

obligation und	der contract	or law to as	sign, grant, con	nvey, or license any			censed or am under is listed below:	an
		, ,						
FULL NAME	Hybridon, I	nc.						
ADDRESS			Milford, MA 0	1757				_
		Individual	X	Small Business Conce	em		Nonprofit Organization	
FULL NAME ADDRESS					· · · · · · · · · · · · · · · · · · ·			_
		Individual	. 🗆	Small Business Conce	ern		Nonprofit Organization	
FULL NAME								
ADDRESS		I altabas al		Carall Dunings Cons			Nanasasi Osaasinatina	_
CHIL NAME	u	Individual	J	Small Business Conce	em		Nonprofit Organization	
FULL NAME ADDRESS							· · · · · · · · · · · · · · · · · · ·	_
ABBALLOG		Individual		Small Business Conce	ern		Nonprofit Organization	_
I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)) I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.								
NAME OF PE	RSON SIGN	IING:	Douglas J. Je	nsen				
TITLE OF PER	RSON SIGN	ING						
OTHER THAN	OWNER:		President & C	CEO				
ADDRESS OF PERSON SIGNING:			OriGenix Technologies, Inc.					
			230 Bernard-Belleau					
			Suite 212					
•			Laval, Quebe	ec H7V 4A9				
SIGNATURE:	_	and the			_ DATE:	May	12,1999	